Viviana Elian

Prof. Dr. Viviana Elian

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2023 in Life
Verified
Journal Article
Open access
PDF file
Viviana ElianViviana Elian
Viviana Elian
Violeta PopoviciVioleta Popovici
Violeta Popovici
Emma Adriana OzonEmma Adriana Ozon
Emma Adriana Ozon
Adina Magdalena MusucAdina Magdalena Musuc
Adina Magdalena Musuc
FAFița Cătălina Ancuța
Fița Cătălina Ancuța
Dumitru N LupuliasaDumitru N Lupuliasa
Dumitru N Lupuliasa
Type 1 diabetes mellitus is a chronic autoimmune disease that affects millions of people and generates high healthcare costs due to frequent complications when inappropriately managed. Our paper aimed to review the latest technologies used in T1DM management for better glycemic control and their impact on daily life for people with diabetes. Continuous glucose monitoring systems provide a better understanding of daily glycemic variations for children and adults and can be easily used. These systems diminish diabetes distress and improve diabetes control by decreasing hypoglycemia. Continuous subcutaneous insulin infusions have proven their benefits in selected patients. There is a tendency to use more complex systems, such as hybrid closed-loop systems that can modulate insulin infusion based on glycemic readings and artificial intelligence-based algorithms. It can help people manage the burdens associated with T1DM management, such as fear of hypoglycemia, exercising, and long-term complications. The future is promising and aims to develop more complex ways of automated control of glycemic levels to diminish the distress of individuals living with diabetes.
1

Verified
Journal Article
Open access
PDF file
Viviana ElianViviana Elian
Viviana Elian
Violeta PopoviciVioleta Popovici
Violeta Popovici
OKOana Karampelas
Oana Karampelas
Gratiela GRADISTEANU PircalabioruGratiela GRADISTEANU Pircalabioru
Gratiela GRADISTEANU Pircalabioru
GRGabriela Radulian
Gabriela Radulian
MMMadalina Musat
Madalina Musat
The primary treatment for autoimmune Diabetes Mellitus (Type 1 Diabetes Mellitus-T1DM) is insulin therapy. Unfortunately, a multitude of clinical cases has demonstrated that the use of insulin as a sole therapeutic intervention fails to address all issues comprehensively. Therefore, non-insulin adjunct treatment has been investigated and shown successful results in clinical trials. Various hypoglycemia-inducing drugs such as Metformin, glucagon-like peptide 1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, amylin analogs, and Sodium-Glucose Cotransporters 2 (SGLT-2) inhibitors, developed good outcomes in patients with T1DM. Currently, SGLT-2 inhibitors have remarkably improved the treatment of patients with diabetes by preventing cardiovascular events, heart failure hospitalization, and progression of renal disease. However, their pharmacological potential has not been explored enough. Thus, the substantial interest in SGLT-2 inhibitors (SGLT-2is) underlines the present review. It begins with an overview of carrier-mediated cellular glucose uptake, evidencing the insulin-independent transport system contribution to glucose homeostasis and the essential roles of Sodium-Glucose Cotransporters 1 and 2. Then, the pharmacological properties of SGLT-2is are detailed, leading to potential applications in treating T1DM patients with automated insulin delivery (AID) systems. Results from several studies demonstrated improvements in glycemic control, an increase in Time in Range (TIR), a decrease in glycemic variability, reduced daily insulin requirements without increasing hyperglycemic events, and benefits in weight management. However, these advantages are counterbalanced by increased risks, particularly concerning Diabetic Ketoacidosis (DKA). Several clinical trials reported a higher incidence of DKA when patients with T1DM received SGLT-2 inhibitors such as Sotagliflozin and Empagliflozin. On the other hand, patients with T1DM and a body mass index (BMI) of ≥27 kg/m2 treated with Dapagliflozin showed similar reduction in hyperglycemia and body weight and insignificantly increased DKA incidence compared to the overall trial population. Additional multicenter and randomized studies are required to establish safer and more effective long-term strategies based on patient selection, education, and continuous ketone body monitoring for optimal integration of SGLT-2 inhibitors into T1DM therapeutic protocol.
1

Verified
Journal Article
Open access
PDF file
Emma Adriana OzonEmma Adriana Ozon
Emma Adriana Ozon
Izabela Dana Maria StanIzabela Dana Maria Stan
Izabela Dana Maria Stan
Mititelu MagdalenaMititelu Magdalena
Mititelu Magdalena
Adina Magdalena MusucAdina Magdalena Musuc
Adina Magdalena Musuc
Bogdan Nicolae ManolescuBogdan Nicolae Manolescu
Bogdan Nicolae Manolescu
Viviana ElianViviana Elian
Viviana Elian
The excess of free radicals causes numerous imbalances in the body that lead to premature aging, the degradation of internal structures, and the appearance of numerous pathologies responsible for the increased risk of premature death. The present work aims to evaluate the physical, chemical, pharmacotechnical, and antioxidant activity of newly achieved capsule formulations. These two formulations were F1a.i., which contains melatonin:biotin:coenzyme Q10 (weight ratio of 1:2:60), and F2a.i., which contains quercetin:resveratrol:biotin:coenzyme Q10 (weight ratio of 10:10:1:10). The adequate selection of the excipient types and amounts for final capsule formulations (F1c.c., F2c.c.) was based on preformulation studies performed on the powders containing active ingredients. The antioxidant activity assessed using three methods (ABTS, DPPH, and FRAP) compared with acid ascorbic as a positive control demonstrated that the F2c.c. formulation possesses the strongest antioxidant capacity. The results confirmed the suitable formulation and the accurate selection of the types and amounts of active ingredients, as well as the auxiliary excipients used in newly developed capsule formulations as supplements with an excellent antioxidant effect on the human body.

Verified
Journal Article
Open access
PDF file
Gratiela GRADISTEANU PircalabioruGratiela GRADISTEANU Pircalabioru
Gratiela GRADISTEANU Pircalabioru
MMMadalina Musat
Madalina Musat
Viviana ElianViviana Elian
Viviana Elian
Ciprian IliescuCiprian Iliescu
Ciprian Iliescu
As the burden of type 2 diabetes (T2D) continues to escalate globally, there is a growing need for novel, less-invasive biomarkers capable of early diabetes detection and monitoring of disease progression. Liquid biopsy, recognized for its minimally invasive nature, is increasingly being applied beyond oncology, and nevertheless shows its potential when the collection of the tissue biopsy is not possible. This diagnostic approach involves utilizing liquid biopsy markers such as cell-free nucleic acids, extracellular vesicles, and diverse metabolites for the molecular diagnosis of T2D and its related complications. In this context, we thoroughly examine recent developments in T2D liquid biopsy research. Additionally, we discuss the primary challenges and future prospects of employing liquid biopsy in the management of T2D. Prognosis, diagnosis and monitoring of T2D through liquid biopsy could be a game-changing technique for personalized diabetes management.

2 January 2016 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
OSOctavian Savu
Octavian Savu
Viviana ElianViviana Elian
Viviana Elian
OSOana Steriade
Oana Steriade
ITIleana Teodoru
Ileana Teodoru
SMStela Mihut
Stela Mihut
CSCristian Serafinceanu
Cristian Serafinceanu

25 June 2023 in Medicina
Verified
Journal Article
Open access
PDF file
EREmilia Rusu
Emilia Rusu
HCHoratiu Coman
Horatiu Coman
ACAndrada Coșoreanu
Andrada Coșoreanu
AMAna-Maria Militaru
Ana-Maria Militaru
HPHorațiu-Cristian Popescu-Vâlceanu
Horațiu-Cristian Popescu-Vâlceanu
GRGabriela Radulian
Gabriela Radulian
Background and Objectives: The primary objective of this study was to investigate the incidence of lower extremity amputations (LEAs) in a representative population from Romania, in both diabetic and non-diabetic adults, including trauma-related amputations. The secondary objective was to evaluate the trends in LEAs and the overall ratio of major-to-minor amputations. Material and Methods: The study was retrospective and included data from the Romanian National Hospital Discharge Records, conducted between 1 January 2015 and 31 December 2019. Results: The overall number of cases with LEAs was 88,102, out of which 38,590 were aterosclerosis-related LEAs, 40,499 were diabetes-related LEAs, and 9013 were trauma-related LEAs, with an ascending trend observed annually for each of these categories. Of the total non-traumatic amputations, 51.2% were in patients with diabetes. Most LEAs were in men. The total incidence increased from 80.61/100,000 in 2015 to 98.15/100,000 in 2019. Conclusions: Our study reported a 21% increase in total LEAs, 22.01% in non-traumatic LEAs, and 19.65% in trauma-related amputation. The minor-to-major amputation ratio increased over the study period in patients with diabetes. According to these findings, it is estimated that currently, in Romania, there is one diabetes-related amputation every hour and one non-traumatic amputation every 30 min.